BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Husereau D. How do we value a cure? Expert Review of Pharmacoeconomics & Outcomes Research 2015;15:551-5. [DOI: 10.1586/14737167.2015.1039519] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Pearson SD, Ollendorf DA, Chapman RH. New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options? Value in Health 2019;22:656-60. [DOI: 10.1016/j.jval.2019.01.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
2 Hettle R, Corbett M, Hinde S, Hodgson R, Jones-Diette J, Woolacott N, Palmer S. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess 2017;21:1-204. [PMID: 28244858 DOI: 10.3310/hta21070] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 15.5] [Reference Citation Analysis]
3 Faulkner E, Spinner DS, Ringo M, Carroll M. Are Global Health Systems Ready for Transformative Therapies? Value in Health 2019;22:627-41. [DOI: 10.1016/j.jval.2019.04.1911] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
4 Aballéa S, Thokagevistk K, Velikanova R, Simoens S, Annemans L, Antonanzas F, Auquier P, François C, Fricke FU, Malone D, Millier A, Persson U, Petrou S, Dabbous O, Postma M, Toumi M. Health economic evaluation of gene replacement therapies: methodological issues and recommendations. J Mark Access Health Policy 2020;8:1822666. [PMID: 33144927 DOI: 10.1080/20016689.2020.1822666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Iskrov G, Vasilev G, Stefanov R. What could gene therapies learn from orphan drugs’ post-regulatory approval access in the EU? Expert Opinion on Orphan Drugs 2019;7:407-14. [DOI: 10.1080/21678707.2019.1663171] [Reference Citation Analysis]
6 Hendriks S, Pearson SD. Assessing potential cures: are there distinctive elements of value beyond health gain? J Comp Eff Res 2021. [PMID: 33663230 DOI: 10.2217/cer-2020-0190] [Reference Citation Analysis]
7 Keech J, Dai WF, Trudeau M, Mercer RE, Naipaul R, Wright FC, Ferguson SE, Darling G, Gavura S, Eisen A, Kouroukis CT, Beca J, Chan KKW. Impact of rarity on Canadian oncology health technology assessment and funding. Int J Technol Assess Health Care 2020;:1-6. [PMID: 32779560 DOI: 10.1017/S0266462320000483] [Reference Citation Analysis]
8 Husereau D, Henshall C, Sampietro-colom L, Thomas S. CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS? Int J Technol Assess Health Care 2016;32:191-9. [DOI: 10.1017/s0266462316000386] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 4.2] [Reference Citation Analysis]
9 Qiu T, Pochopień M, Hanna E, Liang S, Wang Y, Han R, Toumi M, Aballéa S. Challenges in the market access of regenerative medicines, and implications for manufacturers and decision-makers: a systematic review. Regen Med 2022. [PMID: 35042424 DOI: 10.2217/rme-2021-0083] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chapman RH, Kumar VM, Whittington MD, Pearson SD. Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a "Shared Savings" Approach to Cost Offsets. Value Health 2021;24:839-45. [PMID: 34119082 DOI: 10.1016/j.jval.2021.02.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]